资讯内容 Content

ASCO 2023丨黑色素瘤领域重磅研究进展抢先看!
作者:肿瘤瞭望 时间:2023/5/12 13:29:46    加入收藏
 关键字:黑色素瘤 
编者按:美国临床肿瘤学会(ASCO)年会将于当地时间6月2~6日在美国芝加哥举行。作为全球肿瘤领域最具权威的学术盛会,ASCO大会期间将公布当前国际上最前沿的临床肿瘤学科研成果和肿瘤治疗技术。近日,ASCO官网发布了本次会议的日程和摘要题目。黑色素瘤领域多项重磅研究即将公布,其中不乏中国学者报告的研究成果,包括北京大学肿瘤医院郭军教授一项研究入选口头报告,北京大学肿瘤医院斯璐教授、毛丽丽教授各一项研究入选壁报讨论。肿瘤瞭望带您提前速览重磅研究摘要题目。
 
6月2日——Rapid Abstract Session
 
▌Developmental Therapeutics-Immunotherapy
 
摘要号:2515
Intestinal microbiome characterization in immune checkpoint inhibition(ICI)resistant disease.Presenter:
免疫检查点抑制(ICI)耐药疾病中的肠道微生物组特征
讲者:Pavlina Spiliopoulou,MD,PhD|Division of Medical Oncology and Hematology,Princess Margaret Cancer Centre,University Health Network,University of Toronto
 
6月3日——Clinical Science Symposium
 
▌The Promise of Neoadjuvant Immunotherapy Across Solid Tumors
 
摘要号:101
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma:Three-year data of PRADO and OpACIN-neo.
以应答为导向的手术和辅助治疗对Ⅲ期黑色素瘤伊匹木单抗+纳武利尤单抗新辅助治疗后长期生存的影响:PRADO和OpACIN-neo的3年数据
讲者:Irene L.M.Reijers,MD|Netherlands Cancer Institute
 
6月3日——Poster Discussion Session
 
摘要号:9509|Poster Bd#:272
Initial efficacy and safety of RP1+nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.
RP1+纳武利尤单抗在抗PD-1失败的黑色素瘤患者中的初步疗效和安全性:正在进行的1/2期IGNYTE研究
讲者:Bartosz Chmielowski,MD,PhD|Jonsson Comprehensive Cancer Center,University of California Los Angeles
 
摘要号:9510|Poster Bd#:273
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma:A multicenter,open-label,single-arm,phase 2 study.
Tunlametinib用于晚期NRAS突变黑色素瘤患者的疗效和安全性:一项多中心、开放标签、单臂、Ⅱ期研究
讲者:斯璐(北京大学肿瘤医院)
 
摘要号:LBA9512|Poster Bd#:275
Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases:Results from a randomized controlled trial(the SCANDIUM trial).
SCANDIUM试验:隔离肝脏灌注治疗葡萄膜黑色素瘤肝转移的生存率
讲者:Roger Olofsson Bagge,MD,PhD|Gothenburg University
 
摘要号:9513|Poster Bd#:276
Tumor infiltrating lymphocyte(TIL)harvest and ex vivo expansion from primary and metastatic(met)uveal melanoma(UM)tumors.
原发性和转移性葡萄膜黑色素瘤的肿瘤浸润淋巴细胞的采集和体外扩增
讲者:Sapna Pradyuman Patel,MD|The University of Texas MD Anderson Cancer Center
 
摘要号:9514|Poster Bd#:277
NeoPlus:A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.
NeoPlus:仑伐替尼和帕博利珠单抗用于可切除黏膜黑色素瘤新辅助治疗的Ⅱ期研究
讲者:毛丽丽(北京大学肿瘤医院)
 
摘要号:LBA9515|Poster Bd#:278
Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940,a personalized cancer vaccine,and pembrolizumab.
循环肿瘤DNA应用于接受mRNA-4157/V940(个性化肿瘤疫苗)和帕博利珠单抗治疗的已切除的高危黑色素瘤患者的微小残留病灶生物标志物检测
讲者:Matteo S.Carlino,PhD,FRACP,MBBS|Sydney Medical School,Faculty of Medicine and Health Sciences,University of Sydney,Camperdown and Melanoma Institute Australia,Sydney,NSW,Australia,and Crown Princess Mary Cancer Centre,Westmead and Blacktown Hospital
 
摘要号:9516|Poster Bd#:279
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature:A pooled analysis.
基于γ-干扰素特征重新审视可切除的Ⅲ期黑色素瘤的最佳新辅助免疫治疗方案:一项汇总分析
讲者:Minke W.Lucas,MD|Netherlands Cancer Institute
 
摘要号:9517|Poster Bd#:280
Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma(ADAPT-IT).
基于早期放射学评估的晚期黑色素瘤纳武利尤单抗和伊匹木单抗适应性给药的Ⅱ期试验(ADAPT-IT)的最终临床结果和首次转化相关性
讲者:James William Smithy,MD,MHS|Memorial Sloan Kettering Cancer Center
 
摘要号:9518|Poster Bd#:281
Efficacy of adjuvant therapy in patients(pts)with AJCC v8 stage IIIA cutaneous melanoma.
辅助治疗对ⅢA期(AJCC第八版)皮肤黑色素瘤患者的疗效
讲者:Piyush Grover,MBBS,B.Pharm|Melanoma Institute Australia
 
摘要号:9520|Poster Bd#:283
Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
在纳武利尤单抗和伊匹木单抗联合治疗发生严重免疫相关不良事件的晚期黑色素瘤患者中纳武利尤单抗维持治疗的作用
讲者:Anna Maloney,MPH|Frank H Netter MD School of Medicine
 
6月4日——Clinical Science Symposium
 
▌Are Big Data Smart Enough to Answer Questions in Central Nervous System Tumors?
 
摘要号:2012
External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.
临床局限性黑色素瘤患者中枢神经系统转移风险因素的外部验证和列线图
讲者:Merve Hasanov,MD|The University of Texas MD Anderson Cancer Center
6月5日——Oral Abstract Session
 
摘要号:9501
Significant durable response with fianlimab(anti-LAG-3)and cemiplimab(anti-PD-1)in advanced melanoma:Post adjuvant PD-1 analysis.
Fianlimab(抗LAG-3)和西米普利单抗(抗PD-1)在晚期黑色素瘤中的显著持久应答:PD-1辅助治疗后分析
讲者:Omid Hamid,MD|The Angeles Clinic&Research Institute,A Cedars-Sinai Affiliate
 
摘要号:9502
Nivolumab(NIVO)plus relatlimab(RELA)vs NIVO in previously untreated metastatic or unresectable melanoma:2-year results from RELATIVITY-047.
纳武利尤单抗(NIVO)+Relatlimab(RELA)对比NIVO单药在既往未治疗的转移性或不可切除的黑色素瘤中的应用:RELATIVITY-047的2年结果
讲者:Hussein A.Tawbi,MD,PhD|University of Texas MD Anderson Cancer Center
 
摘要号:9511
Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients(pts)with BRAF-mutant(MT)metastatic melanoma(MM)(CTEP P9466).
达拉非尼和曲美替尼±Navitoclax治疗BRAF突变转移性黑色素瘤的随机Ⅱ期试验(CTEP P9466)
讲者:Zeynep Eroglu,MD|H.Lee Moffitt Cancer Center and Research Institute
 
摘要号:LBA9503
Distant metastasis-free survival results from the randomized,phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
mRNA-4157-P201/KEYNOTE-942随机Ⅱ期试验的无远处转移生存结果
讲者:Adnan Khattak,PhD,FRACP,MBBS|One Clinical Research and Edith Cowan University
 
摘要号:9504
Association of biomarkers(BMs)with efficacy of adjuvant nivolumab(NIVO)vs placebo(PBO)in patients with resected stage IIB/C melanoma(CA209-76K).
生物标志物(BMs)与已切除的ⅡB/C期黑色素瘤患者的辅助性纳武利尤单抗(NIVO)和安慰剂(PBO)的疗效的关系(CA209-76K)
讲者:Georgina V.Long,MD,PhD,FRACP|Melanoma Institute Australia,The University of Sydney,and Royal North Shore and Mater Hospitals
 
摘要号:LBA9505
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma:Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
帕博利珠单抗对比安慰剂作为ⅡB或ⅡC期黑色素瘤的辅助治疗:KEYNOTE-716Ⅲ期研究中无远处转移生存的最终分析
讲者:Jason J.Luke,MD,FACP|UPMC Hillman Cancer Center
 
摘要号:9508
Temozolomide plus cisplatin versus toripalimab(anti-PD-1)as adjuvant therapy in resected mucosal melanoma.
替莫唑胺联合顺铂对比特瑞普利单抗(抗PD-1)用于已切除黏膜黑色素瘤的辅助治疗
讲者:郭军(北京大学肿瘤医院)

点击排行 Top Hits

相关幻灯

相关视频

 
关于本站 | 设为首页 | 加入收藏 | 站长邮箱 | 友情链接 | 版权申明

肿瘤瞭望 版权所有  2014-2019 ioncol.com  All Rights Reserved